Clinical trials: T-Lymphocytopenia
Idiopathic CD4 Lymphopenia
A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia
Background: Idiopathic CD4 lymphopenia (ICL) is a syndrome characterized by low levels of certain immune cells called CD4 T cells.
- Trial name
- NCT05600920
- Testing
- Recombinant human interleukin (IL) 7-hyFc
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Idiopathic CD4+ Lymphocytopenia, Cryptococcal Meningitis
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Background: Idiopathic CD4+ lymphocytopenia (ICL) is a condition in which there is a decreased level of CD4+ lymphocytes (a type of white blood cell), which can lead to opportunistic infections or autoimmune disorders and…
- Conditions
- Idiopathic CD4+ Lymphocytopenia, Cryptococcal Meningitis, Warts
- Trial name
- NCT00867269
- Where
- United States
- Volunteers
- 950 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Idiopathic CD4-Positive, T-Lymphocytopenia
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Idiopathic CD4 lymphocytopenia (ICL) is a rare syndrome defined by consistently low CD4 T cell counts (<300/mm^3) without evidence of HIV infection or other known immunodeficiency.
- Trial name
- NCT02015013
- Testing
- Filgrastim, Plerixafor
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Idiopathic CD4 T Cell Lymphocytopenia
Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia
Background: Diseases related to human papillomavirus (HPV) include warts, lesions, and cancers. ICL is idiopathic CD4 T cell lymphocytopenia. People with this rare disease get more HPV-related diseases than other people do.
- Trial name
- NCT03519464
- Testing
- Gardasil 9
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Idiopathic CD4 Lymphopenia
Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)
Background: People with Idiopathic CD4 lymphopenia (ICL) have lower numbers of a type of white blood cell called CD4 cells. White blood cells fight against infections.
- Trial name
- NCT04097561
- Testing
- Belimumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Idiopathic CD4 Lymphocytopenia
Idiopathic CD4 Lymphocytopenia
Definition: Idiopathic CD4+ T lymphocytopenia (ICL) is an immune deficiency first described in 1992 and characterized by the US Centers for Disease Control (CDC) as absolute CD4+ T-lymphocyte count < 300/mm3 or < 20% of total T…
- Trial name
- Lympho-4 (NCT02113930)
- Testing
- Constitution of a biobank of frozen cells, plasma and serum samples, Genetic study
- Where
- France
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myopia, Moderate
To Compare the Clinical Outcomes of FemtoLASIK and ICL Implantation in Treating Moderate Myopia Focusing on Refractive Stability, Contrast Sensitivity and High Order Aberrations.
Compare the clinical outcomes of FemtoLASIK and ICL implantation in treating moderate myopia.
- Trial name
- NCT07291986
- Testing
- FemtoLASIK, ICL implantation
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Walid Osama Abdel Rahman Nour El Din
Large Infarct Core, Post-stroke Lymphocytopenia
Methylprednisolone for Stroke With Large Infarct Core and Post-stroke Lymphocytopenia
The efficacy and safety of early adjunctive methylprednisolone therapy in acute ischemic stroke patients with large infarct cores (ASPECTS score < 6) and post-stroke lymphocytopenia remain unclear.
- Trial name
- MIRACLE-2 (NCT07202143)
- Testing
- Methylprednisolone sodium succinate, Normal Saline
- Where
- China
- Volunteers
- 200 people
- Sponsor
- YiLin
ICL, Vault
Predictive Performance of a Generative Model for Corneal Tomography After ICL Implantation
To evaluate the efficacy of a corneal tomography Imaging model in predicting postoperative vault based on preoperative corneal topography in Implantable Collamer Lens (ICL) surgery.
- Conditions
- ICL, Vault, Deep Learning, AI (Artificial Intelligence)
- Trial name
- NCT07146737
- Testing
- Corneal tomography generation model after ICL surgery
- Where
- China
- Volunteers
- 818 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Hematological Malignancy, Lymphocytopenia
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
To evaluate the efficacy and safety of Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections in the treatment of lymphocytopenia in patients with malignant hematological tumors
- Trial name
- NCT06584006
- Testing
- Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections, Recombinant Human Interleukin-2 Injections
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort)
Comparison of the effects of CYT107 vs Placebo administered by intra-muscular route (IM) at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients
- Trial name
- ILIAD-7-BRA (NCT04927169)
- Testing
- Interleukin-7
- Where
- 6 sites in Brazil
- Volunteers
- 4 people
- Sponsor
- Revimmune
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients
- Trial name
- ILIAD-7-US-O (NCT04426201)
- Testing
- CYT107
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Revimmune
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/ kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.
- Trial name
- ILIAD-7-FR (NCT04407689)
- Testing
- Interleukin-7
- Where
- 6 sites in France
- Volunteers
- 34 people
- Sponsor
- Revimmune
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients
- Trial name
- ILIAD-7-US-I (NCT04442178)
- Testing
- CYT107
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Revimmune
COVID-19, Lymphocytopenia
InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort
Comparison of the effects of CYT107 vs Placebo administered IM at 10µg/kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.
- Trial name
- ILIAD-7-UK (NCT04379076)
- Testing
- Interleukin-7
- Where
- 13 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Revimmune
HIV Seropositivity, CD4+ T Lymphocytopenia
Regional Differences in Human Immunodeficiency Virus (HIV) Testing
This retrospective observational study aims at the examination of regional differences in the procedure of referral for serological HIV testing between eastern (new) and western (old) German federal states.
- Trial name
- HIVRegional (NCT03158987)
- Testing
- Medical record review
- Where
- Germany
- Volunteers
- 999 people
- Sponsor
- Jena University Hospital
HIV-1-infection, CD4+ T Lymphocytopenia
Pyridostigmine as Immunomodulator in People Living With HIV
Human immunodeficiency virus (HIV) infection is characterized by persistent immune activation and a constant turnover of T cells. This leads to a precipitous fall in the number of T cells, as well as to an early immunosenescence.
- Conditions
- HIV-1-infection, CD4+ T Lymphocytopenia, Immune Deficiency, Immuno-senescence
- Trial name
- NCT03312244
- Testing
- Pyridostigmine Bromide
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Idiopathic CD4+ T-Lymphocytopenia
Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)
Background: Idiopathic CD4 lymphocytopenia (ICL) is a condition in which patients have low levels of T cells, a type of white blood cell that helps fight infection.
- Trial name
- NCT00839436
- Testing
- CYT107
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Severe Combined Immunodeficiency, T Cell Lymphocytopenia
Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population
The goal of the proposed research is to establish the validity of a newborn screening method for severe combined immunodeficiency (SCID).
- Trial name
- NCT00845416
- Where
- 2 sites in United States
- Volunteers
- 1,800 people
- Sponsor
- University of California, San Francisco
CD4 Lymphocytopenia, Idiopathic CD4 Positive T Lymphocytopenia
Evaluation of HIV-Negative Patients With Low CD4+ T Lymphocyte Counts
This study will evaluate HIV-negative patients with unusually low levels of CD4+ T lymphocytes (a type of white blood cell) to learn more about the clinical symptoms, cause, immunology, and biology of this problem.
- Trial name
- NCT00001319
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)